You Dongdong, Wang Xiaoyu, Lu Ping, Li Feng
Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
Department of Pediatric Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, PR China.
Ital J Pediatr. 2025 Aug 4;51(1):166. doi: 10.1186/s13052-025-02000-z.
BACKGROUND: Bacterial meningitis (BM) in neonates leads to high mortality rates and long-term complications. Current guidelines recommend repeat cerebrospinal fluid (CSF) examinations to assess treatment efficacy, but their clinical value remains controversial. This study aims to evaluate the clinical utility and prognostic value of repeat CSF parameters within 3-5 days following initial antimicrobial therapy in neonates with BM. METHODS: A retrospective analysis of electronic medical records from January 2017 to December 2022 yielded 241 neonates of diagnosed with neonatal BM upon discharge in our neonatal intensive care unit. Of these, 85 met the stringent inclusion criteria for enrollment. Data on clinical characteristics, laboratory findings, cranial imaging results and other relevant information were collected. The criteria for an adequate response to the initial antimicrobial therapy, established for this study, included a 48-hour afebrile period, negative meningeal irritation signs, a C-reactive protein (CRP) level of ≤ 20 mg/L, and a neutrophil count of ≤ 10,000/mm³. Short-term adverse outcomes were defined as the occurrence of complications during hospitalization or sequelae at discharge. RESULTS: In the analysis of 54 neonates demonstrating an adequate response to initial antimicrobial therapy, a comparison between 29 neonates with repeated CSF parameter measurements and 25 neonates without such measurements revealed no significant differences in antibiotic duration (p = 0.728), complications during hospitalization (p = 0.517), or sequelae at discharge (p = 1.000). A multiple logistic regression analysis of the group with repeated CSF measurements identified elevated CSF protein levels as the only potential risk factor for complications during hospitalization (p = 0.045; OR = 15.046; 95% CI: 1.062-213.089). However, none of the other repeated CSF measurements, such as total leukocyte count in CSF (CSF-TLC), the absolute neutrophil count to total leukocyte count ratio in CSF [CSF-Neutrophil (%)], and CSF glucose, were significant predictors of complications during hospitalizations (P > 0.05 for all). Furthermore, except for CSF-Neutrophil (%), the other repeated CSF measurements were significantly positively correlated with their initial CSF parameters (P < 0.05 for all). In the full cohort of 85 neonates, significant differences were observed between the 54 neonates with an adequate response and the 31 neonates with an inadequate response to therapy. Significant variables included admission weight (p = 0.047), peak blood CRP levels before antibiotic use (p < 0.001), initial CSF protein levels (p = 0.007) and blood culture results (p = 0.037). Both the risk of complications during hospitalization and sequelae at discharge were also significantly different (p < 0.001). In the cohort of 85 neonates, there were significant differences between the 52 neonates without short-term adverse outcomes and the 31 neonates with short-term adverse outcomes. The variables showing significant differences included the presence of neurological symptoms (p = 0.021), peak blood CRP levels before starting antibiotics (p = 0.022), initial CSF glucose levels (p = 0.023), initial CSF protein levels (p = 0.001), and an inadequate response to initial antibiotic therapy (p < 0.001). CONCLUSIONS: For neonates with BM who have shown an adequate response to initial antimicrobial therapy, conducting repeated CSF examinations within the first 3-5 days of treatment appears to have limited value, as it does not provide additional information that could help physicians shorten the duration of antibiotic therapy or reduce the risk of short-term adverse outcomes, such as risk of complications during hospitalizations or sequelae at discharge. In contrast, for the initial assessment of short-term prognosis in neonates newly diagnosed with bacterial meningitis, the clinical global impression (CGI) at admission, particularly factors such as neonatal weight, neurological symptoms, response to initial antimicrobial therapy, and early laboratory data-including peak blood CRP levels before antibiotic use, initial CSF glucose levels, initial CSF protein levels, and blood culture. results [In Table 4, a comparison between neonates with an adequate response to therapy and those without revealed a significant difference in blood culture results (p = 0.025)] -have shown stronger predictive capabilities and deserve greater attention.
背景:新生儿细菌性脑膜炎(BM)可导致高死亡率和长期并发症。当前指南推荐重复进行脑脊液(CSF)检查以评估治疗效果,但其临床价值仍存在争议。本研究旨在评估BM新生儿在初始抗菌治疗后3 - 5天内重复CSF参数的临床效用和预后价值。 方法:对2017年1月至2022年12月的电子病历进行回顾性分析,在我们新生儿重症监护病房出院时确诊为新生儿BM的241例新生儿中,85例符合严格的纳入标准。收集临床特征、实验室检查结果、头颅影像学结果及其他相关信息。本研究设定的对初始抗菌治疗充分反应的标准包括48小时无发热期、脑膜刺激征阴性、C反应蛋白(CRP)水平≤20mg/L以及中性粒细胞计数≤10,000/mm³。短期不良结局定义为住院期间出现并发症或出院时出现后遗症。 结果:在对54例对初始抗菌治疗有充分反应的新生儿进行分析时,比较29例重复进行CSF参数测量的新生儿和25例未进行此类测量的新生儿,发现抗生素使用时长(p = 0.728)、住院期间并发症(p = 0.517)或出院时后遗症(p = 1.000)方面无显著差异。对重复进行CSF测量的组进行多因素逻辑回归分析,发现CSF蛋白水平升高是住院期间并发症的唯一潜在危险因素(p = 0.045;OR = 15.046;95%CI:1.062 - 213.089)。然而,其他重复的CSF测量指标,如CSF总白细胞计数(CSF - TLC)、CSF中绝对中性粒细胞计数与总白细胞计数之比[CSF - 中性粒细胞(%)]以及CSF葡萄糖,均不是住院期间并发症的显著预测指标(所有P>0.05)。此外,除CSF - 中性粒细胞(%)外,其他重复的CSF测量指标与其初始CSF参数均呈显著正相关(所有P<0.05)。在85例新生儿的全队列中,对治疗有充分反应的54例新生儿与反应不充分的31例新生儿之间观察到显著差异。显著变量包括入院体重(p = 0.047)、使用抗生素前血CRP峰值水平(p<0.001)、初始CSF蛋白水平(p = 0.007)和血培养结果(p = 0.037)。住院期间并发症风险和出院时后遗症也存在显著差异(p<0.001)。在85例新生儿队列中,无短期不良结局的52例新生儿与有短期不良结局的31例新生儿之间存在显著差异。显示出显著差异的变量包括神经症状的存在(p = 0.021)、开始使用抗生素前血CRP峰值水平(p = 0.022)、初始CSF葡萄糖水平(p = 0.023)、初始CSF蛋白水平(p = 0.001)以及对初始抗生素治疗反应不充分(p<0.001)。 结论:对于对初始抗菌治疗有充分反应的BM新生儿,在治疗的前3 - 5天内进行重复CSF检查似乎价值有限,因为它并未提供有助于医生缩短抗生素治疗时长或降低短期不良结局风险(如住院期间并发症风险或出院时后遗症)的额外信息。相比之下,对于新诊断为细菌性脑膜炎的新生儿的短期预后初始评估,入院时的临床整体印象(CGI),特别是诸如新生儿体重、神经症状、对初始抗菌治疗的反应以及早期实验室数据(包括使用抗生素前血CRP峰值水平、初始CSF葡萄糖水平、初始CSF蛋白水平和血培养结果[在表4中,对治疗有充分反应的新生儿与无充分反应的新生儿之间血培养结果存在显著差异(p = 0.025)])具有更强的预测能力,值得更多关注。
Cochrane Database Syst Rev. 2018-6-25
Cochrane Database Syst Rev. 2010-3-17
Cochrane Database Syst Rev. 2005-7-20
Cochrane Database Syst Rev. 2014-12-19
Cochrane Database Syst Rev. 2018-5-31
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2018-7-24
Ann Clin Transl Neurol. 2021-5
Pediatr Infect Dis J. 2021-6-1
Hosp Pediatr. 2019-12
Front Neurol. 2018-11-20
BMC Pediatr. 2018-11-2
Am Fam Physician. 2017-9-1